Suggested remit: To appraise the clinical and cost effectiveness of selumetinib within its marketing authorisation for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over.
Status In progress
Process HST
ID number 1590

Provisional Schedule

Committee meeting: 1 10 November 2021
Expected publication 05 May 2022

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors AstraZeneca (selumetinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
  Guy’s and St Thomas’ NHS Foundation Trust
  Manchester University NHS Foundation Trust
Patient carer groups Action for Sick Children
  Brain and Spine Foundation
  Brain Charity
  Genetic Alliance
  Muslim Council of Britain
  National Children's Bureau
  Nerve Tumours UK
  Neurological Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Anaesthetists
  Association of British Neurologists
  Association of Genetic Nurses & Counsellors
  Association of Surgeons of Great Britain and Ireland
  British Neuropathological Society
  British Paediatric Neurology Association
  British Society for Gene and Cell therapy
  British Society for Genetic Medicine
  British Society for Human Genetics
  Institute of Neurology
  Primary Care and Community Neurology Society
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Genetic Testing Network


Associated public health groups Public Health England
  Public Health Wales
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  Cochrane Cystic Fibrosis & Genetic Disorders Group
  Genomics England
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
15 June 2021 In progress. In progress
15 June 2021 Invitation to participate
01 March 2021 Please note that following on from a request received from the company, the timelines for this evaluation have been revised and it is now anticipated to begin in mid-June 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early August 2021. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
21 April 2020 Topic update: this evaluation has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
01 November 2019 (10:00) Scoping workshop (London)
19 September 2019 - 17 October 2019 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance